Press Room

JDRF-Supported Researchers Make Gains in Designing Islet Cell Encapsulation Materials for Use in Type 1 Diabetes Therapies

New study shows size and shape of encapsulation materials have an effect on islet cell survival

Read More

BD and Medtronic Collaborate to Introduce a New Infusion Set with BD FlowSmart Technology Designed to Improve Insulin Pump Therapy

BD Medical, a segment of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), and Medtronic (NYSE: MDT) today announced a collaboration to introduce a new insulin pump infusion set with BD FlowSmart™ technology​


BD Receives FDA Clearance for a Novel Infusion Set with BD FlowSmart Technology to Enhance the Use of Insulin Pumps

BD Medical, a segment of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), announced today it has received 510(k) clearance from the U.S. Food and Drug Administration for a new insulin infusion set with BD FlowSmartTM  technology. 


14-Year-Old from Vancouver to Represent Canada at JDRF 2015 Children's Congress

Jack, 14 of Vancouver, has big plans for this summer. He has been selected by JDRF to join 160 other children from around the world in Washington, D.C., to remind U.S. Members of Congress of the vital need to continue supporting research that aims to reduce the burden they all share of liv...


JDRF in the Globe and Mail, April 1, 2015: Improving the chances for healthy pregnancies.

JDRF showcases the CONCEPPT trial, including quotes from Dr. Lois Donovan, Medical Director of diabetes in pregnancy in Calgary - Alberta Health Services and Dr. Helen Murphy in Cambridge, U.K., who are co-principal investigators overseeing Canadian and international sites. The story also provi...


ViaCyte Receives Clearance from Health Canada for Diabetes Clinical Trial

ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of diabetes in clinical trials, has received a No Objection Letter from Health Canada providing clearance to proceed with sites in Canada for the Compa...


JDRF Announces New Partnership with the European Foundation for the Study of Diabetes and Eli Lilly and Company to Fund Novel Diabetes Research

JDRF, the leading research and advocacy organization funding type 1 diabetes (T1D) research announced today a new research partnership with the European Foundation for the Study of Diabetes (EFSD) and Eli Lilly and Company to establish a new research funding program to accelerate type 1 diabetes dis...


Stem cells show promise for reversing Type 2 diabetes

Scientists at the University of British Columbia and BetaLogics, part of Janssen Research & Development, LLC have shown for the first time that Type 2 diabetes can be effectively treated with a combination of specially-cultured stem cells and conventional diabetes drugs.


JDRF in the Globe and Mail, November 25, 2014: For kids, research and new treatment options bring less discomfort and better outcomes

JDRF showcases advancements in CGM technology in making monitoring of glucose levels better and the new experimental encapsulated cell replacement therapy.


JDRF-Funded Islet Encapsulation Program Reaches Historic Milestone

First Ever Person with Type 1 Diabetes Receives Experimental Encapsulated Human Stem Cell-Derived Beta Cell Replacement Therapy


Lets turn type one into type none